showed that METTL3 enhances the expression of BHLHE41 by facilitating m6A modifications, subsequently leading to the increased transcription of CXCL1 and CXCR2. This enhances the migration and accumulation of MDSCs in the tumor microenvironment, ultimately suppressing the activation and proliferation of CD8+ T cells and other immune cells. The gene discussed is CXCR2; the disease is neoplasm.